| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC1429 |
| Trial ID | NCT01676259 |
| Disease | Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | siG12D LODER |
| Co-treatment | Gemcitabine+nab-Paclitaxel|Folfirinox |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer |
| Year | 2018 |
| Country | United States|Israel |
| Company sponsor | Silenseed Ltd |
| Other ID(s) | SLSG12D-P2 |
| Cohort 1 | |||||||||
|
|||||||||